AWS Recognizes Agilisium As One Of 13 Global Partners With Both Generative AI And Life Sciences Consulting Competencies
Agilisium transforms the Life Sciences value chain with 20+ Gen AI solutions, accelerated by AWS advanced services.
Post thi"We are pleased that AWS has recognized Agilisium's investments and success in over two dozen GenAI solutions specifically targeting the Life Sciences industry, including, Gene Inspector, Drug Watch and MLR Review. By deploying GenAI solutions, we are empowering our clients to accelerate discoveries, enhance patient outcomes, and take informed decisions. This recognition reinforces our dedication to building scalable, future-ready AI solutions that will shape the next era of Life Sciences," said Raj Babu, Founder & CEO, Agilisium.
About Agilisium:
Agilisium is one of the leading Data Innovation Partners for the Life Sciences industry. The company delivers cutting-edge solutions that drive impactful change by combining our strong domain expertise with Data, Cloud, GenAI, and Advanced Analytics. Agilisium collaborates with leading pharma and biotech companies to provide data-driven insights and innovative solutions across the value chain, helping accelerate drug discovery, optimize patient care, achieve commercial success, streamline product delivery, and foster collaboration. Learn more at
About Agilisium's AWS Migration Acceleration Program (MAP):
Agilisium prides itself in having more than 450 AWS - certified professionals working for over 20 Fortune 500 Life Sciences clients. Agilisium enables its clients to leverage AWS' MAP (Migration Acceleration Program) funding program and offers a no-cost assessment program to accelerate their cloud transformation journeys.
To learn more: Agilisium Consulting
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment